Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD276 CAR-T in Refractory Pancreatic Cancer
NCT05143151Phase 2Unknown
- Sponsor
- Shenzhen University General Hospital
- Start
- Jul 2021
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD276 autologous chimeric antigen receptor T cells in pancreatic cancer (PC), sponsored by Shenzhen University General Hospital. Status: unknown.
02
Drugs
CD276 autologous chimeric antigen receptor T cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05143151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143151.